迪巧品牌怎么样 申请店铺

我要投票 迪巧在钙片行业中的票数:163 更新时间:2025-01-22
迪巧是哪个国家的品牌?「迪巧」是安士制药(中山)有限公司旗下著名品牌。该品牌发源于广东,由创始人徐清波在2003-09-19期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
迪巧怎么样

迪巧是由美国安士制药有限公司按F.LA标准在美国生产的品牌产品。精选全球50多个优质钙源,是经过国际先进工艺提纯的精制碳酸钙,安全性极高。迪巧科学添加了维生素D3,具有安全、足量、好吸收的三大优点。同时,迪巧针对中国不同年龄段人群对钙制剂需求的特点,特别设计了个性配方和口味。有专为0-3岁宝宝设计的迪巧小儿碳酸钙D3颗粒,专为3岁以上儿童设计的迪巧儿童维D钙咀嚼片,专为成人计的迪巧维D钙咀嚼片以及专为更年期女性设计的迪巧秀源女性片。

迪巧是中国优生科学协会唯一推荐钙补充剂,经中国优生科学协会审核论证,连续10年被作为唯一推荐补钙制剂。2010年中国家庭药箱调查显示,迪巧名列中国居民信赖的家庭常备药排名前三。该调查由中国非处方药物协会、中国医药质量管理协会、中国药学会发布。迪巧荣获中国健康年度总评榜“最受欢迎补钙用药”。2010年39健康网开展了健康年度总评榜,由网民自行投票选出最欢迎的药品品牌,迪巧荣获最受欢迎补钙用药之一。迪巧连续3年荣获“健康中国2010中国药品品牌榜”上榜品牌称号。迪巧连续3年荣获“2008-2009年度店员推荐率最高品牌”。2009年10月29日至31日,《中国药店》杂志社举办了第九届中国药店高峰论坛暨"2008-2009年度店员推荐率最高品牌"揭晓会议,来自全国连锁店、及卫生部、国家药监局的百余人到场。迪巧深受药店专业人员信赖,被大会评为“2008-2009年度店员推荐率最高品牌”。这已经是迪巧连续三年荣获此奖项。

安士制药(中山)有限公司位于广东省中山市火炬开发区国家健康基地,是由以美国安士集团有限公司,中山市健康科技产业基地发展有限公司和百洋集团有限公司为主的几家公司共同投资的一家集科研开发、生产和市场建设于一体的新型医药生产企业。

公司首期占地面积二万多平方米,拥有近一万四千平方米的现代化厂房,已建成两个固体制剂车间、冻干粉针车间、软胶囊车间和质检中心。全部生产车间都通过了国家和省食品药品监督管理局认证中心的GMP认证。固体制剂车间于2010年5月通过美国FDA现场验证。

安士以科研开发为先导,研究开发自产产品。同时引进国外先进生产技术及产品信息,已形成的迪巧系列补钙制剂为国内名列前茅的大品种。此外,安士一直致力于处方药出口美国为主攻目标,培育一支适应国际化生产要求的管理团队和员工队伍。

2007年3月,安士生物科技(中山)有限公司成立,专门从事保健品的软胶囊研发和生产,从而满足软胶囊制剂在国内外市场销售快速发展的需要。

安士制药(中山)有限公司的宗旨是进一步提高安士品牌的美誉度和信任度,极大地丰富安士与人类健康息息相关的品牌内涵。公司的目标是建立一个适应新剂型、新品种发展的药品生产基地,努力在制药市场上形成一个重要的、诚信可靠的企业,为人类的健康事业做出贡献。

Diqiao is a brand product manufactured in the United States by axis Pharmaceutical Co., Ltd. according to f.la standard. More than 50 high-quality calcium sources in the world are selected. They are refined calcium carbonate purified by international advanced technology, with high safety. Diqiao added vitamin D3 scientifically, which has three advantages of safety, sufficient quantity and good absorption. At the same time, Diqiao specially designed the individual formula and taste according to the characteristics of different age groups in China. There are Diqiao children's calcium carbonate D3 granules specially designed for 0-3 years old children, Diqiao children's vitamin D calcium chewable tablets specially designed for children over 3 years old, Diqiao vitamin D calcium chewable tablets specially designed for adults and Diqiao Xiuyuan women's tablets specially designed for menopausal women. Diqiao is the only calcium supplement recommended by China eugenics Association. It has been the only calcium supplement recommended by China eugenics Association for 10 consecutive years. According to the 2010 survey of family medicine kits in China, Diqiao ranked in the top three list of household medicines trusted by Chinese residents. The survey was released by China over the counter drug association, China Pharmaceutical Quality Management Association and China Pharmaceutical Association. Diqiao won the "most popular calcium supplement" in China's annual health review. In 2010, 39 health.com launched the annual health evaluation list, and the Internet users voted to select the most popular drug brand. Diqiao won one of the most popular calcium supplements. Diqiao has won the title of "healthy China 2010 Chinese drug brand list" for three consecutive years. Diqiao has been awarded "the highest brand recommended by shop assistants in 2008-2009" for three consecutive years. From October 29 to 31, 2009, China drugstore magazine Co., Ltd. held the 9th China drugstore Summit Forum and the unveiling meeting of "the highest recommended brand of staff in 2008-2009". More than 100 people from the national chain stores, the Ministry of health and the State Food and Drug Administration attended. Diqiao is deeply trusted by drugstore professionals and was rated as the "top brand with the highest recommended rate of salesmen in 2008-2009" by the conference. This is the third consecutive year that Diqiao has won this award. Anshi Pharmaceutical (Zhongshan) Co., Ltd. is located in the national health base of Torch Development Zone, Zhongshan City, Guangdong Province. It is a new pharmaceutical production enterprise, which is jointly invested by several companies mainly including Anshi Group Co., Ltd., Zhongshan Health Science and Technology Industrial Base Development Co., Ltd. and Baiyang Group Co., Ltd. The first phase of the company covers an area of more than 20000 square meters, with a modern plant of nearly 14000 square meters. Two solid preparation workshops, freeze-dried powder injection workshops, soft capsule workshops and quality inspection centers have been built. All production workshops have passed the GMP certification of national and provincial food and Drug Administration certification center. The solid preparation workshop passed the FDA field verification in May 2010. With scientific research and development as the guide, axis researches and develops its own products. At the same time, the introduction of foreign advanced production technology and product information, has formed Diqiao series of calcium supplements for the domestic top big varieties. In addition, axis has been committed to the export of prescription drugs to the United States as the main goal, and cultivate a management team and staff team to meet the requirements of international production. In March 2007, axis Biotechnology (Zhongshan) Co., Ltd. was established, specializing in the research, development and production of soft capsules for health products, so as to meet the needs of rapid development of soft capsule sales in domestic and foreign markets. The aim of axis Pharmaceutical (Zhongshan) Co., Ltd. is to further improve the reputation and trust of axis brand and greatly enrich the brand connotation of axis closely related to human health. The company's goal is to establish a pharmaceutical production base to adapt to the development of new dosage forms and new varieties, strive to form an important, honest and reliable enterprise in the pharmaceutical market, and make contributions to human health.

本文链接: https://brand.waitui.com/7cdc17c05.html 联系电话:076023898866

千城特选小程序码

7×24h 快讯

英国政府借款大幅增加,遵守财政规则面临挑战

英国政府2024年12月预算赤字激增,在利率居高不下、经济增长疲软的情况下,英国政府在遵守财政规则方面面临挑战。英国国家统计局周三表示,12月政府支出超过收入178亿英镑(219.9亿美元),赤字比去年同期高出101亿英镑,远高于预算责任办公室预测的142亿英镑。推动这一增长的一个因素是利息支付,比2023年同期高出38亿英镑。(新浪财经)

2小时前

策源资本旗下基金入股灵童机器人

36氪获悉,天眼查App显示,近日,灵童机器人(上海)有限公司发生工商变更,新增成都策源广益数字经济股权投资基金合伙企业(有限合伙)、成都高新策源共创企业管理咨询合伙企业(有限合伙)为股东,同时注册资本由103万人民币增至约115.9万人民币。灵童机器人(上海)有限公司成立于2022年8月,法定代表人为陆杰,经营范围含智能机器人的研发、智能机器人销售、服务消费机器人销售、人工智能硬件销售、人工智能应用软件开发、数字内容制作服务等。

2小时前

百万tokens降价至0.8元后,豆包模型毛利率已能达到50%

从多个知情人士处获悉,豆包大模型去年大幅降价后,毛利率依然为正。其中,字节跳动最新推出的豆包大模型1.5,在推理成本优化上取得进一步突破。在火山引擎上售卖API的Doubao-1.5-pro,毛利率仍能达到50%。去年5月,字节跳动正式对外发布豆包大模型。其中,豆包通用模型pro-32k版,模型推理输入价格仅每百万tokens0.8元,而当时市场上同规格模型的定价一般为每百万tokens120元,是豆包模型价格的150倍。(界面)

2小时前

华林证券:2024年净利同比预增973.03%—1288.62%

36氪获悉,华林证券发布业绩预告,预计2024年归母净利3.4亿元—4.4亿元,同比增长973.03%—1288.62%。公司持续推进科技金融转型战略,财富管理线上业务收入同比大幅增加。自营投资业务积极把握市场机遇,进一步提升配置资产能力,收入大幅增加。此外,公司针对红博会展信托受益权资产支持专项计划仲裁事项,于2023年度计提预计负债约2.28亿元,导致2024年度相关营业外支出同比大幅下降。该笔营业外支出为非经常性损益。

2小时前

北京君羊商贸有限公司获千万级Pre-A轮融资

36氪获悉,近日,北京君羊商贸有限公司宣布获得腾信投资领投的Pre-A轮千万级融资。公司创始人邵群表示,本轮融资资金主要投入到开拓业务、技术创新和拓宽市场这三大核心领域,同时将投入大量资金用于AI 算法的优化和模型训练。

2小时前

本页详细列出关于龙牡的品牌信息,含品牌所属公司介绍,龙牡所处行业的品牌地位及优势。
咨询